S&P 500   4,977.40 (-0.67%)
DOW   37,962.62 (+0.50%)
QQQ   418.07 (-1.26%)
AAPL   165.21 (-1.10%)
MSFT   401.21 (-0.76%)
META   486.91 (-2.97%)
GOOGL   154.59 (-0.91%)
AMZN   175.51 (-2.07%)
TSLA   148.94 (-0.66%)
NVDA   804.39 (-5.00%)
AMD   149.63 (-3.51%)
NIO   3.84 (-4.00%)
BABA   68.98 (+0.15%)
T   16.42 (+0.55%)
F   12.14 (+0.66%)
MU   107.35 (-4.09%)
GE   149.95 (-1.96%)
CGC   8.16 (+4.21%)
DIS   112.41 (-0.02%)
AMC   3.25 (+11.30%)
PFE   25.85 (+1.81%)
PYPL   62.32 (+0.35%)
XOM   120.12 (+1.35%)
S&P 500   4,977.40 (-0.67%)
DOW   37,962.62 (+0.50%)
QQQ   418.07 (-1.26%)
AAPL   165.21 (-1.10%)
MSFT   401.21 (-0.76%)
META   486.91 (-2.97%)
GOOGL   154.59 (-0.91%)
AMZN   175.51 (-2.07%)
TSLA   148.94 (-0.66%)
NVDA   804.39 (-5.00%)
AMD   149.63 (-3.51%)
NIO   3.84 (-4.00%)
BABA   68.98 (+0.15%)
T   16.42 (+0.55%)
F   12.14 (+0.66%)
MU   107.35 (-4.09%)
GE   149.95 (-1.96%)
CGC   8.16 (+4.21%)
DIS   112.41 (-0.02%)
AMC   3.25 (+11.30%)
PFE   25.85 (+1.81%)
PYPL   62.32 (+0.35%)
XOM   120.12 (+1.35%)
S&P 500   4,977.40 (-0.67%)
DOW   37,962.62 (+0.50%)
QQQ   418.07 (-1.26%)
AAPL   165.21 (-1.10%)
MSFT   401.21 (-0.76%)
META   486.91 (-2.97%)
GOOGL   154.59 (-0.91%)
AMZN   175.51 (-2.07%)
TSLA   148.94 (-0.66%)
NVDA   804.39 (-5.00%)
AMD   149.63 (-3.51%)
NIO   3.84 (-4.00%)
BABA   68.98 (+0.15%)
T   16.42 (+0.55%)
F   12.14 (+0.66%)
MU   107.35 (-4.09%)
GE   149.95 (-1.96%)
CGC   8.16 (+4.21%)
DIS   112.41 (-0.02%)
AMC   3.25 (+11.30%)
PFE   25.85 (+1.81%)
PYPL   62.32 (+0.35%)
XOM   120.12 (+1.35%)
S&P 500   4,977.40 (-0.67%)
DOW   37,962.62 (+0.50%)
QQQ   418.07 (-1.26%)
AAPL   165.21 (-1.10%)
MSFT   401.21 (-0.76%)
META   486.91 (-2.97%)
GOOGL   154.59 (-0.91%)
AMZN   175.51 (-2.07%)
TSLA   148.94 (-0.66%)
NVDA   804.39 (-5.00%)
AMD   149.63 (-3.51%)
NIO   3.84 (-4.00%)
BABA   68.98 (+0.15%)
T   16.42 (+0.55%)
F   12.14 (+0.66%)
MU   107.35 (-4.09%)
GE   149.95 (-1.96%)
CGC   8.16 (+4.21%)
DIS   112.41 (-0.02%)
AMC   3.25 (+11.30%)
PFE   25.85 (+1.81%)
PYPL   62.32 (+0.35%)
XOM   120.12 (+1.35%)
NASDAQ:IMV

IMV (IMV) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.49
$0.91
52-Week Range
N/A
Volume
44,800 shs
Average Volume
233,607 shs
Market Capitalization
$9.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IMV stock logo

About IMV Stock (NASDAQ:IMV)

IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.

IMV Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Philippines sales up in February 2024
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Q4 2023 Horizon Technology Finance Corp Earnings Call
Don't Fall For These 12 Fried Chicken Myths
See More Headlines
Receive IMV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
4/19/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMV
Fax
N/A
Employees
97
Year Founded
N/A

Profitability

Net Income
$-37,990,000.00
Net Margins
-11,547.42%
Pretax Margin
-11,547.42%
Return on Equity
-12,695.41%

Debt

Sales & Book Value

Annual Sales
$330,000.00
Book Value
($0.69) per share

Miscellaneous

Free Float
11,673,000
Market Cap
$9.63 million
Optionable
Optionable
Beta
0.95
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Andrew Hall
    Chief Executive Office & Director
  • Jennifer Schmitke
    Chief Operating Officer
  • Brittany Davison
    Chief Accounting Officer, Director & SVP-finance
  • Jeremy R. Graff
    Chief Scientific Officer
  • Stéphane Fiset
    Vice President-Clinical Research

IMV Stock Analysis - Frequently Asked Questions

Should I buy or sell IMV stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMV in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" IMV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IMV, but not buy additional shares or sell existing shares.
View IMV analyst ratings
or view top-rated stocks.

How were IMV's earnings last quarter?

IMV Inc. (NASDAQ:IMV) released its quarterly earnings data on Thursday, November, 11th. The company reported ($1.30) earnings per share for the quarter, meeting the consensus estimate of ($1.30). The business earned $0.04 million during the quarter. IMV had a negative trailing twelve-month return on equity of 12,695.41% and a negative net margin of 11,547.42%. During the same quarter last year, the firm posted ($1.00) EPS.

When did IMV's stock split?

Shares of IMV reverse split before market open on Tuesday, December 13th 2022. The 1-10 reverse split was announced on Tuesday, December 13th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

This page (NASDAQ:IMV) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners